Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986591 | 0.83 | CYP11B1 (0.45) | SIGMAR1CYP11B1CYP11B2CHRNA7HTR3A | |
| SCHEMBL3986068 | 0.80 | KDM4E (0.44) | HRH3SIGMAR1CHRNA7CHRM2CHRM4 | |
| SCHEMBL3981098 | 0.79 | SIGMAR1 (0.44) | HRH3SIGMAR1KDM2BCHRM2CHRM4 | |
| SCHEMBL3988522 | 0.79 | DYRK1A (0.45) | HRH3CYP11B1CYP11B2CHRM2CHRM4 | |
| SCHEMBL13965256 | 0.76 | SIGMAR1 (0.40) | SIGMAR1CYP11B1CYP11B2CHRNA7HTR3A | |
| SCHEMBL3990816 | 0.73 | TRPV6 (0.46) | HRH3SIGMAR1 | |
| SCHEMBL4701391 | 0.73 | CHRNA7 (0.42) | KDM2BUSP30CHRNA7HTR3A | |
| SCHEMBL13940636 | 0.71 | KMT2A (0.41) | CYP11B1CYP11B2KDM2BCXCR1 | |
| SCHEMBL10160789 | 0.70 | CYP1A2 (0.44) | CA12CA1CA2CA9PLCG2 | |
| SCHEMBL3991069 | 0.69 | HCRTR1 (0.41) | SIGMAR1USP30CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | CHRND, CHRNE, CHRM2 | HRH3 74/4885SIGMAR1 140/4885CYP11B1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.